Viridian Therapeutics, Inc. announced on October 23, 2025 that it has priced an underwritten public offering of 11,425,000 shares of its common stock at $22.00 per share, generating $251 million in gross proceeds.
The offering is underwritten by Jefferies, Leerink Partners, Evercore ISI, Stifel, and Wedbush PacGrow, and the company has granted the underwriters a 30‑day option to purchase additional shares. In addition, the offering includes Series B non‑voting convertible preferred stock that can be converted into 66.67 shares of common stock per preferred share.
Proceeds from the offering will be used to fund the commercial launch of Viridian’s lead candidates, veligrotug and VRDN‑003, as well as to support ongoing research and development activities, working capital needs, and general corporate purposes.
This financing follows a recent $300 million royalty‑financing deal and provides the company with a substantial cash cushion to advance its pipeline and support the anticipated launch of its thyroid eye disease therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.